KIO 101
Alternative Names: KIO 101; PaniDrop; PaniJect; PP-001 - Panoptes PharmaLatest Information Update: 28 Jan 2024
At a glance
- Originator 4SC Discovery
- Developer Kiora Pharmaceuticals; Panoptes Pharma
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Dry eyes
- Phase I/II Uveitis
- Preclinical Unspecified
- No development reported Conjunctivitis; Infectious conjunctivitis; Keratoconjunctivitis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Conjunctivitis in Unknown (Ophthalmic, Drops)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Dry-eyes in Unknown (Ophthalmic, Drops)
- 21 Sep 2023 Kiora Pharmaceuticals suspends a phase II trial for Dry eyes (In adults, In elderly) in Australia (Ophthalmic) (Drops) (NCT05629364)